MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Zacks01-02

Shares of Monopar Therapeutics MNPR, a clinical-stage biotech, skyrocketed 383.5% in the past three months fueled by a licensing agreement with AstraZeneca AZN, which granted MNPR an exclusive ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500974072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 23:02","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500974072","market":"us","top_or_hot":-1,"title":"MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN","media":"Zacks","content":"<div>\n<p>Shares of Monopar Therapeutics MNPR, a clinical-stage biotech, skyrocketed 383.5% in the past three months fueled by a licensing agreement with AstraZeneca AZN, which granted MNPR an exclusive ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mnpr-stock-skyrockets-384-3-150200991.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMNPR Stock Skyrockets 384% in 3 Months After Deal With AZN\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-02 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mnpr-stock-skyrockets-384-3-150200991.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Monopar Therapeutics MNPR, a clinical-stage biotech, skyrocketed 383.5% in the past three months fueled by a licensing agreement with AstraZeneca AZN, which granted MNPR an exclusive ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mnpr-stock-skyrockets-384-3-150200991.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2417539215.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/mnpr-stock-skyrockets-384-3-150200991.html","article_id":"2500974072","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500974072","pubTimestamp":1735830120,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Monopar Therapeutics MNPR, a clinical-stage biotech, skyrocketed 383.5% in the past three months fueled by a licensing agreement with AstraZeneca AZN, which granted MNPR an exclusive worldwide license to ALXN-1840 . ALXN-1840 is an investigational once-daily, oral medicine, which is being developed for treating Wilson disease, a rare and progressive genetic disease.AstraZeneca had earlier announced that a pivotal phase III study evaluating the candidate for the above indication had met its primary endpoint. Although AZN terminated the ALXN-1840 program in 2023, Monopar took up the candidate upon the request of the Wilson Disease Association. AstraZeneca’s termination of the ALXN-1840 program was based on the review of results from phase II mechanistic studies and discussions with regulatory authorities.In the past six months, shares of Monopar have rallied 525.5% against the industry’s 4.8% decline.Some other top-ranked stocks from the sector areCastle BiosciencesCSTL andSper","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","CSTL":"Castle Biosciences, Inc.","BK4007":"制药","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","MNPR":"Monopar Therapeutics","BK4196":"保健护理服务","BK4588":"碎股","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","AZN":"阿斯利康","SPRO":"Spero Therapeutics Inc.","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4568":"美国抗疫概念"},"translate_title":"与AZN达成交易后，MNPR股价在3个月内飙升384%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRO":1,"MNPR":1,"CSTL":1,"AZN":1},"content_text":"Shares of Monopar Therapeutics MNPR, a clinical-stage biotech, skyrocketed 383.5% in the past three months fueled by a licensing agreement with AstraZeneca AZN, which granted MNPR an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate). ALXN-1840 is an investigational once-daily, oral medicine, which is being developed for treating Wilson disease, a rare and progressive genetic disease.\nAstraZeneca had earlier announced that a pivotal phase III study evaluating the candidate for the above indication had met its primary endpoint. Although AZN terminated the ALXN-1840 program in 2023, Monopar took up the candidate upon the request of the Wilson Disease Association. AstraZeneca’s termination of the ALXN-1840 program was based on the review of results from phase II mechanistic studies and discussions with regulatory authorities.\nIn the past six months, shares of Monopar have rallied 525.5% against the industry’s 4.8% decline.\nImage Source: Zacks Investment Research\nMore on the Licensing Deal Between MNPR and AZN\nThe licensing agreement with AstraZeneca added a late-stage candidate to Monopar’s early-stage pipeline. This has brought MNPR significantly close to becoming a commercial-stage company.\nFollowing the deal, Monopar has assumed responsibilities for all future global development and commercialization activities related to ALXN-1840 to treat Wilson disease. Management believes that the company’s expertise in rare disease drug development and commercialization will catapult ALXN-1840 into a successful product for the above indication.\nUnder the terms of the transaction, Monopar is liable to make an undisclosed upfront cash payment to AstraZeneca, along with a stake in its equity, in consideration of the global rights to ALXN-1840. The company shall also be liable to make additional payments to AZN based on the achievement of certain pre-determined regulatory and sales milestones. AstraZeneca is also eligible to receive tiered royalties on net sales from Monopar if ALXN-1840 is approved and launched.\nPer MNPR, ALXN-1840 has significant market opportunity as one in 30,000 live births in the United States are affected by Wilson disease.\nMonopar will initially be focusing on developing ALXN-1840 for patients with more severe Wilson disease symptoms. It is gearing up to hold discussions with the FDA to figure out a path forward for the candidate.\nApart from ALXN-1840, the company is currently evaluating several other candidates for various oncology indications in separate early-stage studies.\n\nMonopar Therapeutics Inc. Price and Consensus\n\nMonopar Therapeutics Inc. price-consensus-chart | Monopar Therapeutics Inc. Quote\n\nMNPR’s Zacks Rank & Other Stocks to Consider\nMonopar currently sports a Zacks Rank #1 (Strong Buy).\nSome other top-ranked stocks from the sector are Castle Biosciences CSTL and Spero Therapeutics SPRO, each presently sporting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past three months, shares of Castle Biosciences have lost 6.2%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 20.2%.\nSPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAstraZeneca PLC (AZN) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nMonopar Therapeutics Inc. (MNPR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500974072"}